These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 26524472)

  • 21. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.
    Simonin F; Slowe S; Becker JA; Matthes HW; Filliol D; Chluba J; Kitchen I; Kieffer BL
    Eur J Pharmacol; 2001 Mar; 414(2-3):189-95. PubMed ID: 11239918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
    Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
    Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
    Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
    Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
    J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic Characterization of Substituted Nitazenes at
    Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
    J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
    Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orvinols with mixed kappa/mu opioid receptor agonist activity.
    Greedy BM; Bradbury F; Thomas MP; Grivas K; Cami-Kobeci G; Archambeau A; Bosse K; Clark MJ; Aceto M; Lewis JW; Traynor JR; Husbands SM
    J Med Chem; 2013 Apr; 56(8):3207-16. PubMed ID: 23438330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
    Huang H; Wang W; Xu X; Zhu C; Wang Y; Liu J; Li W; Fu W
    Eur J Med Chem; 2020 Mar; 189():112070. PubMed ID: 31982651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
    Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
    J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
    Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
    J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
    Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
    J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
    Zádor F; Kocsis D; Borsodi A; Benyhe S
    Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse.
    Morrison FG; Van Orden LJ; Zeitz K; Kuijer EJ; Smith SL; Heal DJ; Wallace TL
    Neuropharmacology; 2024 Oct; 257():110037. PubMed ID: 38876309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
    Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation.
    Ji RR; Zhang Q; Law PY; Low HH; Elde R; Hökfelt T
    J Neurosci; 1995 Dec; 15(12):8156-66. PubMed ID: 8613750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.